A Comparison of the Intubating Laryngeal Mask FASTRACH™ and the Intubating Laryngeal Mask Ambu Aura-i™
Launched by ASKLEPIOS KLINIKEN HAMBURG GMBH · Apr 11, 2017
Trial Information
Current as of May 18, 2025
Completed
Keywords
ClinConnect Summary
Eighty patients undergoing general anaesthesia with planned tracheal intubation for elective surgical procedures are enrolled in the study after checking for inclusion and exclusion criteria. Patients are randomised to either LMA group for blind tracheal intubation with either a standard PVC tracheal tube, or a specifically for the LMA Fastrach developed tube, yielding 4 subgroups.
After a standardised anaesthesia induction, blind intubation is performed in each study group. Different time intervals are documented, such as time to first adequate lung ventilation, or f.e. time for laryngeal...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients undergoing planned general anaesthesia
- • planned tracheal intubation
- • elective surgical procedure
- • 15 to 80 years of age
- Exclusion Criteria:
- • ASA physical status IV and V
- • severe pulmonary comorbidity (COPD GOLD \>III, bronchial asthma)
- • indication for rapid-sequence induction
- • mouth opening (interincisor distance) \<3cm
- • morbid obesity (BMI \>35kg.m-2)
About Asklepios Kliniken Hamburg Gmbh
Asklepios Kliniken Hamburg GmbH is a leading private hospital operator in Germany, renowned for its commitment to high-quality patient care and innovative medical practices. With a strong focus on research and development, Asklepios actively engages in clinical trials to advance medical knowledge and enhance treatment options across various specialties. The organization is dedicated to fostering collaboration between healthcare professionals and researchers, ensuring the highest ethical standards and regulatory compliance in all clinical research initiatives. Through its state-of-the-art facilities and multidisciplinary approach, Asklepios Kliniken Hamburg GmbH aims to contribute significantly to the field of medicine and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Berthold Bein, Prof. Dr.
Study Chair
Asklepios Kliniken Hamburg GmbH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials